Higher expression of ABCG2 was observed in the patient group ≤ 65 years for LUSC, SARC, SKCM, and BLCA, whereas for thymoma (THYM), KIRP, and LIHC in the group > 65 years (Figure 5A). Here, ABCG2 is linked to bladder transitional cell carcinoma.